JP4785140B2 - Food material having lipid metabolism regulating action, health food, animal feed and animal breeding method - Google Patents

Food material having lipid metabolism regulating action, health food, animal feed and animal breeding method Download PDF

Info

Publication number
JP4785140B2
JP4785140B2 JP2006531398A JP2006531398A JP4785140B2 JP 4785140 B2 JP4785140 B2 JP 4785140B2 JP 2006531398 A JP2006531398 A JP 2006531398A JP 2006531398 A JP2006531398 A JP 2006531398A JP 4785140 B2 JP4785140 B2 JP 4785140B2
Authority
JP
Japan
Prior art keywords
residue
action
lipid metabolism
animal
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2006531398A
Other languages
Japanese (ja)
Other versions
JPWO2006013750A1 (en
Inventor
秀樹 潮
和幸 大原
友照 山崎
繁晴 金本
裕之 前原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Satake Corp
Tokyo University of Marine Science and Technology NUC
Original Assignee
Satake Corp
Tokyo University of Marine Science and Technology NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Satake Corp, Tokyo University of Marine Science and Technology NUC filed Critical Satake Corp
Priority to JP2006531398A priority Critical patent/JP4785140B2/en
Publication of JPWO2006013750A1 publication Critical patent/JPWO2006013750A1/en
Application granted granted Critical
Publication of JP4785140B2 publication Critical patent/JP4785140B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/899Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K10/00Animal feeding-stuffs
    • A23K10/30Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A23K10/37Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms from waste material
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10Cereal-derived products
    • A23L7/115Cereal fibre products, e.g. bran, husk
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P60/00Technologies relating to agriculture, livestock or agroalimentary industries
    • Y02P60/80Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
    • Y02P60/87Re-use of by-products of food processing for fodder production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)

Description

本発明は脂質代謝調節作用を有し、肥満や生活習慣病の予防と改善に役立つ食品素材、健康食品、動物用飼料及びこの動物用飼料を与えて飼育する動物の飼育方法に関するものである。   The present invention relates to a food material, a health food, an animal feed, and a method for raising an animal that is fed and fed with an animal feed that has a lipid metabolism regulating action and is useful for the prevention and improvement of obesity and lifestyle-related diseases.

米糠には植物性の油が大量に含まれているので、米糠は食用油の原料として大量に使用されている。また、米糠にはビタミン、ミネラル、食物繊維など様々な栄養成分が含まれる他に、種々の生理活性機能を有する有用な成分が大量に含まれているので、その抽出物が薬剤、食品添加剤、飼料添加剤等の原料として広く利用されている。   Since rice bran contains a large amount of vegetable oil, rice bran is used in large quantities as a raw material for cooking oil. In addition, rice bran contains various nutrients such as vitamins, minerals, and dietary fiber, and also contains a large amount of useful ingredients having various physiologically active functions. It is widely used as a raw material for feed additives.

ところで、米糠が食用油の原料として使用される場合や米糠の抽出物から薬剤、食品添加剤、飼料添加剤等が作られる場合、米糠からこれらを抜き取った後に脱脂糠(有機溶媒等で油分を除いた糠)、残滓糠(脱脂糠から更に水溶性成分を除いた滓)が大量に残る。   By the way, when rice bran is used as a raw material for edible oil, or when pharmaceuticals, food additives, feed additives, etc. are made from rice bran extracts, after removing these from rice bran, oil is removed with an organic solvent. A large amount of residue left) and residue (a residue obtained by further removing water-soluble components from the defatted residue) remain.

これら脱脂糠、残滓糠は上述した有用成分を抜き取った残り滓なので、有用成分は残っていないだろうと思われ、含有成分の利用は全く考えられておらず、精米の助剤、飼料の増量剤、堆肥の原料位にしか使われていなかった。   Since these defatted rice bran and residue are residual rice cakes from which the above-mentioned useful ingredients have been extracted, it seems that no useful ingredients will remain, and the use of the ingredients is not considered at all. It was only used as a raw material for compost.

特開2001−327881JP 2001-327881 A 特開平05−194069JP 05-194069 A 特開平05−192091JP 05-192091 A

解決しようとする問題点は、大量に発生する脱脂糠や残滓糠が有効に利用されていない点である。   A problem to be solved is that a large amount of defatted soot and residue are not effectively used.

そこで、本発明者等は脱脂糠、残滓糠について鋭意研究し、脱脂糠、残滓糠にはまだ有用成分、特に人や動物の脂質の代謝を調節する働きを有する成分、すなわち血中アディポネクチン濃度を上昇させたり、インスリン耐性を低下させる作用を有する成分がかなり含まれていることを発見し、本発明をなすに至った。   Therefore, the present inventors have conducted intensive research on defatted lees and residues, and found that degreased lees and residues still have useful components, particularly components that have a function of regulating lipid metabolism in humans and animals, that is, blood adiponectin concentration. It was discovered that a component having an action to increase or decrease insulin resistance was considerably contained, and the present invention was made.

本発明は、脱脂糠、残滓糠中に残存している成分に着目して人や動物の脂質代謝を調節し、肥満や生活習慣病を予防したり改善するようにしたことを最も主要な特徴とする。   The main feature of the present invention is that it regulates lipid metabolism in humans and animals by paying attention to components remaining in defatted lees and residues to prevent or improve obesity and lifestyle-related diseases. And

すなわち、本発明に係る脂質代謝調節作用を有する食品素材は脱脂糠又は残滓糠からなることを特徴とするものである。また、本発明に係る脂質代謝調節作用を有する健康食品は脱脂糠又は残滓糠を成分の一つとしていることを特徴とするものである。   That is, the food material having a lipid metabolism regulating action according to the present invention is characterized by comprising defatted koji or residue. In addition, the health food having a lipid metabolism regulating action according to the present invention is characterized in that defatted koji or residue is one of the components.

ここで、脂質代謝調節作用とは、人間や動物の体内の脂質代謝を活性化させ、肥満を予防したり解消させ、また生活習慣病を予防したり解消させる作用をいう。また、食品素材とは、人間が摂取する食品の材料になる素材のみならず、動物が摂取する飼料の材料になる素材をいう。   Here, the lipid metabolism regulating action means the action of activating lipid metabolism in the body of a human being or animal, preventing or eliminating obesity, and preventing or eliminating lifestyle-related diseases. The food material means not only a material that becomes a food material for human consumption but also a material that becomes a feed material for animal consumption.

また、脱脂糠とは、穀類を搗精する際に得られる糠からnヘキサン等の有機溶媒で油分を抽出した残り滓あるいは圧搾によって油を絞り出した絞り滓をいい、残滓糠とは、脱脂糠から水で水溶性成分を抽出した残り滓をいう。   In addition, the defatted lees refers to the remaining lees obtained by extracting oil from noodles or other organic solvents from the lees obtained when scouring cereals or the squeezed lees obtained by squeezing the oil. Remaining rice cake obtained by extracting water-soluble components with water.

また、脱脂糠又は残滓糠は血中アディポネクチン濃度上昇作用又はインスリン耐性を低下させる作用を有する画分を含んでおり、この画分としてはヒドロキシ桂皮酸類縁体植物性ステロールエステル類を挙げることができる。   Further, defatted lees or residues include a fraction having an effect of increasing blood adiponectin concentration or an effect of decreasing insulin resistance, and examples of this fraction include hydroxycinnamic acid analog plant sterol esters. .

なお、脱脂糠と残滓糠は抗肥満および抗生活習慣病の効果に大差はないので、動物用飼料に添加する糠は、脱脂糠でもよいし、残滓糠でもよい。   It should be noted that defatted lees and residues are not significantly different in the effects of anti-obesity and anti-lifestyle diseases, and therefore, the lees added to animal feed may be defatted lees or residues.

また、本発明に係る脂質代謝調節作用を有する動物用飼料は脱脂糠又は残滓糠を成分の一つとしていることを特徴とするものである。また、本発明に係る動物の飼育方法は、脱脂糠又は残滓糠を成分の一つとしている動物用飼料を与えて動物を飼育することを特徴とするものである。   Moreover, the animal feed having a lipid metabolism regulating action according to the present invention is characterized in that defatted koji or residue is one of the components. In addition, the animal breeding method according to the present invention is characterized in that an animal is fed by feeding an animal feed containing defatted straw or residue as one of its components.

ここで、動物用飼料の基本的成分は一般に使用されている動物用飼料と略同一でよい。また、動物用飼料は食い付きを良くするために有る程度の脂質が含まれているものが好ましい。   Here, the basic components of the animal feed may be substantially the same as the animal feed that is generally used. Further, the animal feed preferably contains a certain amount of lipid in order to improve eating.

脂質には、飼料の原料に初めから含まれていた油脂類や、後から添加した油脂類が含まれる。後から添加した油脂類としては、例えばなたね油、大豆油、コーン油、やし油、ひまし油、豚脂、牛脂、魚油、鯨油又はこれらの油から選択された1種又は2種以上の混合油を挙げることができる。   Lipids include fats and oils that were originally included in feed materials and fats and oils that were added later. The oils and fats added later include, for example, rapeseed oil, soybean oil, corn oil, palm oil, castor oil, pork fat, beef tallow, fish oil, whale oil, or one or more mixed oils selected from these oils. Can be mentioned.

脂質が含まれている動物用飼料としては、脂質を1〜20重量%含有し、且つ脱脂糠又は残滓糠を1〜15重量%(有効成分ヒドロキシ桂皮酸類縁体植物性ステロールエステル類量として飼料100gあたり20〜300μg程度)含有するものを挙げることができる。   Animal feeds containing lipids include 1 to 20% by weight of lipids and 1 to 15% by weight of defatted lees or residues (feeds as active ingredient hydroxycinnamic acid analog plant sterol esters) (About 20 to 300 μg per 100 g).

脂質の含有量を1〜20重量%と限定した理由は、脂質の含有量が1重量%未満ではペットや家畜の食い付きが悪くなり、脂質の含有量が20重量%を越えると飼料としてのペレット成形が困難になるからである。   The reason why the lipid content is limited to 1 to 20% by weight is that when the lipid content is less than 1% by weight, the bite of pets and livestock becomes poor, and when the lipid content exceeds 20% by weight, This is because pellet molding becomes difficult.

また、脱脂糠又は残滓糠を1〜15重量%と限定した理由は、脱脂糠又は残滓糠が1重量%未満では抗肥満の効果が小さく、脱脂糠又は残滓糠が15重量%を越えると他の必須成分が少なくなり過ぎ、栄養バランスの悪い飼料になってしまうが、脱脂糠又は残滓糠を1〜15重量%とすれば栄養バランスが良く且つ抗肥満および抗生活習慣病の効果が得られるからである。   Further, the reason for limiting the defatted residue or residue to 1 to 15% by weight is that the effect of anti-obesity is small if the defatted residue or residue is less than 1% by weight, and if the defatted residue or residue exceeds 15% by weight, However, if the defatted lees or residue is 1 to 15% by weight, the nutritional balance is good and the effects of anti-obesity and anti-lifestyle diseases can be obtained. Because.

なお、本発明に係る脂質代謝調節作用を有する動物用飼料及び動物の飼育方法において、抗肥満および抗生活習慣病の顕著な効果が得られるという見地から、前記脂質として食用油脂類が3〜10重量%、前記脱脂糠又は残滓糠が5〜10重量%の範囲が特に好ましい。   From the standpoint that remarkable effects of anti-obesity and anti-lifestyle diseases can be obtained in the animal feed and the animal breeding method having a lipid metabolism regulating action according to the present invention, 3 to 10 edible fats and oils are used as the lipid. A range of 5% by weight to 10% by weight of the defatted soot or residue is particularly preferred.

また、脱脂糠又は残滓糠は血中アディポネクチン濃度上昇作用又はインスリン耐性を低下させる作用を有する画分を含んでおり、この画分としてはヒドロキシ桂皮酸類縁体植物性ステロールエステル類が挙げられることは、上述した食品素材や健康食品の場合と同様である。   In addition, defatted lees or residues include a fraction having an effect of increasing blood adiponectin concentration or reducing insulin resistance, and this fraction includes hydroxycinnamic acid analog plant sterol esters. This is the same as in the case of the food materials and health foods described above.

本発明によれば、今まで有効に利用されていなかった脱脂糠や残滓糠を、食品素材、健康食品、動物用飼料等の原料として有効に利用することができるという効果がある。   According to the present invention, there is an effect that defatted lees and residues that have not been effectively used until now can be effectively used as raw materials for food materials, health foods, animal feeds and the like.

また、本発明によれば、人間やペット又は家畜の肥満の体質を改善し、糖尿病などの生活習慣病を予防したり改善させることができる安全性の高い食品素材、健康食品及び動物用飼料を安価に提供することができるという効果がある。   Further, according to the present invention, a highly safe food material, health food and animal feed that can improve the obesity of human beings, pets or livestock, and prevent or improve lifestyle-related diseases such as diabetes. There is an effect that it can be provided at low cost.

また、本発明によれば、油分を添加して食べ易くしても、摂取する人間やペット又は家畜が肥満や糖尿病などになり難い食品素材、健康食品及び動物用飼料を提供することができるという効果がある。   In addition, according to the present invention, it is possible to provide food materials, health foods, and animal feeds that are less likely to cause obesity, diabetes, etc. even if humans, pets or livestock are ingested even if they are easy to eat by adding oil. effective.

残滓糠の含有量(重量%)と血中アディポネクチン値(μg/ml)との関係を示すグラフである。It is a graph which shows the relationship between content (weight%) of a residue, and blood adiponectin level (microgram / ml). 残滓糠の含有量(重量%)と肥満度(×10−2g/m)との関係を示すグラフである。The content of residue bran is a graph showing the relationship between (wt%) and the degree of obesity (× 10 -2 g / m 2 ). マウス3T3−L1脂肪細胞におけるアディポネクチン分泌量に及ぼす各種成分の効果を示すグラフである。It is a graph which shows the effect of various components which acts on the adiponectin secretion amount in a mouse | mouth 3T3-L1 fat cell. 試験に用いたマウスのHOMAインスリン耐性インデックスを示すグラフである。It is a graph which shows the HOMA insulin resistance index of the mouse | mouth used for the test. 米糠及び残滓糠各1kg中のヒドロキシ桂皮酸類縁体植物性ステロールエステル類の含有量(mg)を示すグラフである。It is a graph which shows content (mg) of the hydroxycinnamic acid analog plant sterol ester in 1 kg of rice bran and each residue. 米糠及び残滓糠について、含有全脂質1kg中のヒドロキシ桂皮酸類縁体植物性ステロールエステル類の含有量(mg)を示すグラフである。It is a graph which shows content (mg) of hydroxycinnamic acid analog plant sterol ester in 1 kg of total lipid containing rice bran and residue.

人間やペット又は家畜の肥満の体質を改善し、糖尿病などの生活習慣病を予防したり改善させるという目的を、低コストで、安全性を損なわずに実現した。   The aim of improving the obesity of humans, pets and livestock, and preventing or improving lifestyle-related diseases such as diabetes has been realized at low cost without compromising safety.

平成13年度広島産コシヒカリより得られた米糠200gに対し、1リットルの特級ヘキサンを加え、カップ型ホモジナイザーで12000回転、5分間均一に撹拌した後、No.1濾紙にて吸引濾過を行った。この操作を再度繰り返した後、得られた脱脂糠をエバボレーターにてヘキサン除去した。   To 200 g of rice bran obtained from Hiroshima Koshihikari in 2001, 1 liter of special grade hexane was added, and the mixture was stirred uniformly at 12,000 rpm for 5 minutes with a cup-type homogenizer. Suction filtration was performed with one filter paper. After repeating this operation again, the obtained defatted soot was removed with hexane by an evaporator.

次に、得られた脱脂糠に2倍量の蒸留水を加え、カップ型ホモジナイザーで12000回転、5分間均一に撹拌した後、5000xg、20分間の遠心分離にて糠を沈殿として回収した。再度、蒸留水によって水溶性成分を抽出し、遠心分離後、得られた残滓糠をエバポレーターおよび室温放置によって乾燥させた。   Next, twice the amount of distilled water was added to the obtained defatted soot, and the mixture was stirred uniformly at 12,000 rpm for 5 minutes with a cup-type homogenizer, and then the soot was collected as a precipitate by centrifugation at 5000 × g for 20 minutes. Again, the water-soluble component was extracted with distilled water, and after centrifugation, the obtained residue was dried by being allowed to stand at an evaporator and at room temperature.

次に、表1に示すように、上記のようにして得られた残滓糠を0〜15重量%、食用油脂類を1〜20重量%、含有する試験飼料を作製した。また、表1に示す成分中、残滓糠の代わりに粗繊維としてセルロースを5重量%、食用油としてコーン油を6重量%とした標準飼料を作成した。   Next, as shown in Table 1, a test feed containing 0 to 15% by weight of the residue obtained as described above and 1 to 20% by weight of edible fats and oils was prepared. In addition, in the components shown in Table 1, a standard feed was prepared with 5% by weight of cellulose as crude fibers and 6% by weight of corn oil as edible oil instead of residue.

Figure 0004785140
Figure 0004785140

次に、明暗(12h/12h)および23℃に調節された実験動物飼育施設中において7週令のC57BL/6J Jclマウス雄120尾を無作為に30群に分け、4尾ずつケージに入れて飼育を行った。   Next, 120 male 7-week-old C57BL / 6J Jcl mice were randomly divided into 30 groups in a laboratory animal breeding facility adjusted to light and dark (12h / 12h) and 23 ° C., and 4 mice were placed in cages. Raised.

まず、予備飼育として1週間、標準飼料を投与して飼育し、その後、3週にわたって試験飼料を投与した。飼料はマウスに飽食摂取させるために一匹一日あたり約5gを投与した。   First, as a preliminary breeding, a standard feed was administered for 1 week for breeding, and then a test diet was administered for 3 weeks. About 5 g of feed was administered per day to feed mice with satiation.

次に、マウスの肥満度(×10−2g/m)及び血中アディポネクチン値(μg/ml)を調べたところ、表2に示す通りであった。血中アディポネクチン値の測定には、ELISA測定キット(大塚製薬)を用いた。Next, when the obesity level (× 10 −2 g / m 2 ) and blood adiponectin level (μg / ml) of the mouse were examined, they were as shown in Table 2. An ELISA measurement kit (Otsuka Pharmaceutical Co., Ltd.) was used for measuring the blood adiponectin level.

Figure 0004785140
Figure 0004785140

表2に示された結果を元に作成した図1から、残滓糠が0重量%の場合のマウスの血中アディポネクチン値(μg/ml)と比較して、残滓糠が1重量%以上ではマウスの血中アディポネクチン値(μg/ml)が高くなることがわかる。また、残滓糠の含有量(重量%)が増えるにつれてマウスの血中アディポネクチン値(μg/ml)が高くなることがわかる。   From FIG. 1 created based on the results shown in Table 2, compared to the mouse adiponectin level (μg / ml) when the residue was 0% by weight, the mouse was found to have a residue of 1% by weight or more. It can be seen that the blood adiponectin level (μg / ml) increases. It can also be seen that the adiponectin level (μg / ml) in the blood of mice increases as the residue content (% by weight) increases.

また、表2に示された結果を元に作成した図2から、残滓糠が0重量%の場合のマウスの肥満度(×10−2g/m)と比較して、残滓糠が1重量%以上ではマウスの肥満度(×10−2g/m)が低くなることがわかる。ここで、肥満度においては、短期的には、残滓糠1%では効果が緩慢であると考えられるが、5%になると、短期的にも効果が認められてくることがわかる。また、残滓糠の含有量(重量%)が増えるにつれて肥満度(×10−2g/m)が低くなることがわかる。なお、食用油脂が15重量%を越えた場合、飼料をペレット状に成形することが困難であった。Moreover, from FIG. 2 created based on the results shown in Table 2, the residue was 1 in comparison with the obesity level of the mouse (× 10 −2 g / m 2 ) when the residue was 0% by weight. in% by weight or more it can be seen that the degree of obesity in mice (× 10 -2 g / m 2 ) is lowered. Here, in the degree of obesity, in the short term, the effect is considered to be slow when the balance is 1%, but when it becomes 5%, the effect is recognized even in the short term. The content of residue bran obesity as (wt%) increases (× 10 -2 g / m 2 ) it can be seen that lower. In addition, when edible oil and fat exceeded 15 weight%, it was difficult to shape | mold a feed into a pellet form.

次に、抗肥満および抗生活習慣病効果を示す有効成分を明らかにするための実験を行った。   Next, an experiment was conducted to clarify the active ingredients having anti-obesity and anti-lifestyle disease effects.

穀類糠において、n−ヘキサンのような非極性溶媒によって抽出されにくく、クロロホルム・メタノール混合溶媒などの比較的極性の高い溶媒によって抽出されやすい画分には、植物性ステロール、フェルラ酸、植物性ステロールフェルラ酸エステル類などが存在する。そこで、これらの標品もしくは混合物による脂肪細胞のアディポネクチン分泌調節作用について検討を加えた。   In fractions that are difficult to extract with a non-polar solvent such as n-hexane in cereal meal and that are easily extracted with a relatively polar solvent such as a chloroform / methanol mixed solvent, plant sterols, ferulic acid, plant sterols Ferulic acid esters exist. Therefore, the effect of adipocyte adiponectin secretion regulation by these preparations or mixtures was examined.

ポジティブコントロールとして、2型糖尿病治療薬として用いられ、脂肪細胞のアディポネクチン分泌を増強することが既に知られているトログリタゾン、試験物質として植物性ステロール混合物、コレステロール、ヒドロキシ桂皮酸類縁体植物性ステロールエステル、フェルラ酸を用い、これらがマウス脂肪細胞によるアディポネクチン分泌に及ぼす影響を調べた。   As a positive control, used as a therapeutic agent for type 2 diabetes, troglitazone already known to enhance adiponectin secretion in adipocytes, plant sterol mixture as test substance, cholesterol, hydroxycinnamic acid analog plant sterol ester, The effect of ferulic acid on adiponectin secretion by mouse adipocytes was examined using ferulic acid.

すなわち、3T3−L1線維芽細胞を10%牛胎児血清(FBS)を含むダルベッコ改変イーグル培地(DMEM)にて培養してコンフルエントに達した後、1μMデキサメサゾン、0.5mMイソブチルメチルキサンチンおよび5μg/mlインスリンを含む10%FBS−DMEMにて分化誘導した。   That is, 3T3-L1 fibroblasts were cultured in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS) to reach confluence, and then 1 μM dexamethasone, 0.5 mM isobutylmethylxanthine and 5 μg / ml Differentiation was induced with 10% FBS-DMEM containing insulin.

7日後、分化した3T3−L1脂肪細胞に1μmol/lの上述の試験物質を含む10%FBS−DMEMを投与し、24時間後に培養上清を採取してアディポネクチンELISAキット(大塚製薬)にてアディポネクチン濃度を測定したところ、図3に示す通りであった。   Seven days later, 10% FBS-DMEM containing 1 μmol / l of the above-mentioned test substance was administered to differentiated 3T3-L1 adipocytes. After 24 hours, the culture supernatant was collected, and adiponectin was used with adiponectin ELISA kit (Otsuka Pharmaceutical). When the concentration was measured, it was as shown in FIG.

図3に示すように、トログリタゾン添加区と同様に、ヒドロキシ桂皮酸類縁体植物性ステロールエステルは3T3−L1脂肪細胞におけるアディポネクチン分泌を有意に増強した(P<0.01)。一方、他の植物性ステロール、フェルラ酸およびコレステロール添加区ではコントロール区と比して差が認められなかった。以上のことから、本発明における有効成分はヒドロキシ桂皮酸類縁体植物性ステロールエステル類であるものと考えられた。   As shown in FIG. 3, similar to the troglitazone-added group, hydroxycinnamic acid analog plant sterol ester significantly enhanced adiponectin secretion in 3T3-L1 adipocytes (P <0.01). On the other hand, no difference was observed in other plant sterol, ferulic acid and cholesterol added groups as compared to the control group. From the above, the active ingredient in the present invention was considered to be hydroxycinnamic acid analog plant sterol esters.

C57BL/6Jclマウスに、5%残滓糠と10%食用油脂とを含む飼料あるいは10%食用油脂だけを含む残滓糠を含まない飼料を与え、実施例1と同様にして、3週間に亘って飼育した。そして、これらのマウス5尾ずつについてグルコースを経口投与し、血液中グルコース含量およびインスリンレベルを定量した。そして、この定量の結果を用いてインスリン耐性の指標であるHOMA-IRインデックス(糖負荷前のインスリンレベル×血中グルコース濃度/22.5)を算出した。結果は図4のグラフに示す通りであった。   C57BL / 6Jcl mice were fed a feed containing 5% residue and 10% edible fat or fat, or a feed containing no residue containing only 10% edible fat and oil, and reared for 3 weeks in the same manner as in Example 1. did. Then, glucose was orally administered to each of these 5 mice, and blood glucose content and insulin level were quantified. The HOMA-IR index (insulin level before glucose load × blood glucose concentration / 22.5), which is an index of insulin resistance, was calculated using the results of this quantification. The results were as shown in the graph of FIG.

なお、血中グルコースについては和光純薬工業株式会社のグルコースCII−テストワコーキットを用いて定量し、インスリンについては株式会社シバヤギのレビスインスリン−マウスELISAキットを用いて定量した。   In addition, blood glucose was quantified using a glucose CII-Test Wako kit manufactured by Wako Pure Chemical Industries, Ltd., and insulin was quantified using a Levis insulin-mouse ELISA kit manufactured by Shibayagi Co., Ltd.

図4に示す通り、残滓糠を含有する試験飼料を用いた区で明らかにインスリン耐性が低下し、改善されていることがわかる。従って、残滓糠を摂取したマウスではインスリン耐性が改善され、インスリンによる血糖低下が速やかに起こること、すなわち残滓糠には2型糖尿病を改善する作用が存在することがわかる。   As shown in FIG. 4, it can be seen that insulin resistance was clearly reduced and improved in the group using the test feed containing residue. Therefore, it can be seen that in mice taking residue, insulin resistance is improved, and blood glucose lowering due to insulin occurs quickly, that is, residue has an action to improve type 2 diabetes.

米糠および残滓糠からクロロホルム・メタノール混合溶媒にて全脂質を抽出し、HPLC分析によってヒドロキシ桂皮酸類縁体植物性ステロールエステル類を定量した。そして、糠1kg当たりのヒドロキシ桂皮酸類縁体植物性ステロールエステル類(mg)として表したところ、図5に示す通りであった。この結果から、残滓糠には米糠に匹敵する量のヒドロキシ桂皮酸類縁体植物性ステロールエステル類が残存していることがわかる。   Total lipids were extracted from rice bran and residue with a mixed solvent of chloroform and methanol, and hydroxycinnamic acid analog plant sterol esters were quantified by HPLC analysis. And when expressed as hydroxycinnamic acid analog plant sterol esters (mg) per 1 kg of straw, it was as shown in FIG. From this result, it can be seen that the residue has an amount of hydroxycinnamic acid analog plant sterol esters comparable to that of rice bran.

また、上記定量の結果を、全脂質1kg当たりのヒドロキシ桂皮酸類縁体植物性ステロールエステル類(mg)として表したところ、図6に示す通りであった。この結果から、全脂質当たりのヒドロキシ桂皮酸類縁体植物性ステロールエステル類の濃度は、残滓糠では米糠の4倍以上も高く、特異的に残存していることが分かる。   The results of the above quantification were expressed as hydroxycinnamic acid analog plant sterol esters (mg) per 1 kg of total lipid, as shown in FIG. From this result, it can be seen that the concentration of hydroxycinnamic acid analog plant sterol esters per total lipid is more than 4 times higher than that of rice bran in the residue and remains specifically.

Claims (5)

米糠を非極性有機溶媒で脱脂し、得られた脱脂糠から水溶性成分を除去した残り滓である残滓糠からなることを特徴とする脂質代謝調節作用を有する食品素材。A food material having a lipid metabolism-regulating action, comprising a residue, which is a residue obtained by degreasing rice bran with a non-polar organic solvent and removing water-soluble components from the obtained defatted residue. 前記残滓糠が、血中アディポネクチン濃度上昇作用と、インスリン耐性を低下させる作用とを有する画分を含み、該画分がヒドロキシ桂皮酸類縁体植物性ステロールエステル類であることを特徴とする請求項1に記載の食品素材。  The residue comprises a fraction having an action of increasing blood adiponectin concentration and an action of reducing insulin resistance, wherein the fraction is a hydroxycinnamic acid analog plant sterol ester. The food material according to 1. 米糠を非極性有機溶媒で脱脂し、得られた脱脂糠から水溶性成分を除去した残り滓である残滓糠を原料素材の一つとしていることを特徴とする脂質代謝調節作用を有する健康食品。A health food having a lipid metabolism-regulating action characterized by using as a raw material a residue, which is a residue obtained by degreasing rice bran with a nonpolar organic solvent and removing water-soluble components from the obtained degreased pork. 前記残滓糠が、血中アディポネクチン濃度上昇作用と、インスリン耐性を低下させる作用とを有する画分を含み、該画分がヒドロキシ桂皮酸類縁体植物性ステロールエステル類であることを特徴とする請求項3に記載の健康食品。  The residue comprises a fraction having an action of increasing blood adiponectin concentration and an action of reducing insulin resistance, wherein the fraction is a hydroxycinnamic acid analog plant sterol ester. 3. The health food according to 3. 米糠を非極性有機溶媒で脱脂し、得られた脱脂糠から水溶性成分を除去した残り滓である残滓糠を5〜10重量%含有し、食用油脂類を3〜10重量%含有していることを特徴とする動物用飼料。 The rice bran is degreased with a non-polar organic solvent, the residue obtained by removing water-soluble components from the obtained degreased koji contains 5 to 10% by weight, and the cooking fats and oils contain 3 to 10% by weight. Animal feed characterized by this.
JP2006531398A 2004-08-04 2005-07-26 Food material having lipid metabolism regulating action, health food, animal feed and animal breeding method Active JP4785140B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006531398A JP4785140B2 (en) 2004-08-04 2005-07-26 Food material having lipid metabolism regulating action, health food, animal feed and animal breeding method

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004227822 2004-08-04
JP2004227822 2004-08-04
JP2006531398A JP4785140B2 (en) 2004-08-04 2005-07-26 Food material having lipid metabolism regulating action, health food, animal feed and animal breeding method
PCT/JP2005/013630 WO2006013750A1 (en) 2004-08-04 2005-07-26 Food material having effect of controlling lipid metabolism, health food, animal feed and methd of feeding animal

Publications (2)

Publication Number Publication Date
JPWO2006013750A1 JPWO2006013750A1 (en) 2008-07-31
JP4785140B2 true JP4785140B2 (en) 2011-10-05

Family

ID=35787040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006531398A Active JP4785140B2 (en) 2004-08-04 2005-07-26 Food material having lipid metabolism regulating action, health food, animal feed and animal breeding method

Country Status (2)

Country Link
JP (1) JP4785140B2 (en)
WO (1) WO2006013750A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008099448A1 (en) * 2007-02-09 2008-08-21 Masayoshi Yamaguchi Preventive/therapeutic agent for diabetic diseases
JP5499415B2 (en) * 2009-09-18 2014-05-21 国立大学法人東京海洋大学 Adiponectin secretion regulator
EP3466418A1 (en) 2011-07-15 2019-04-10 NuSirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
BR112015010947A2 (en) 2012-11-13 2018-06-05 Nusirt Sciences Inc compositions and methods for increasing energy metabolism.
WO2014149280A1 (en) * 2013-03-15 2014-09-25 Nusirt Sciences, Inc. Treatment of pets with sirtuin activators

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0725779A (en) * 1993-06-25 1995-01-27 Yakurigaku Chuo Kenkyusho:Kk Lipase inhibitor derived from embryo bud of defatted rice
JP2001097880A (en) * 1999-09-28 2001-04-10 Otsuka Pharmaceut Factory Inc Lipase inhibitor derived from nonfat rice bran
JP2002316939A (en) * 2001-04-18 2002-10-31 Real:Kk alpha-GLUCOSIDASE INHIBITOR AND PROCESSED FOOD, HYPERGLYCEMIA MEDICINE, FEED AND ADDITIVE CONTAINING THE SAME
JP2004091462A (en) * 2002-09-02 2004-03-25 Oriza Yuka Kk Carbohydrate absorption inhibitor
JP2005068132A (en) * 2003-08-06 2005-03-17 Enkaku Iryo Kenkyusho:Kk Adiponectin secretion promoter, and anti-arteriosclerosis agent, anti-obesity agent, antidiabetic mellitus agent, food additive, functional food and feed additive containing adiponectin secretion promoter

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0725779A (en) * 1993-06-25 1995-01-27 Yakurigaku Chuo Kenkyusho:Kk Lipase inhibitor derived from embryo bud of defatted rice
JP2001097880A (en) * 1999-09-28 2001-04-10 Otsuka Pharmaceut Factory Inc Lipase inhibitor derived from nonfat rice bran
JP2002316939A (en) * 2001-04-18 2002-10-31 Real:Kk alpha-GLUCOSIDASE INHIBITOR AND PROCESSED FOOD, HYPERGLYCEMIA MEDICINE, FEED AND ADDITIVE CONTAINING THE SAME
JP2004091462A (en) * 2002-09-02 2004-03-25 Oriza Yuka Kk Carbohydrate absorption inhibitor
JP2005068132A (en) * 2003-08-06 2005-03-17 Enkaku Iryo Kenkyusho:Kk Adiponectin secretion promoter, and anti-arteriosclerosis agent, anti-obesity agent, antidiabetic mellitus agent, food additive, functional food and feed additive containing adiponectin secretion promoter

Also Published As

Publication number Publication date
WO2006013750A1 (en) 2006-02-09
JPWO2006013750A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
Lai et al. Nutritional studies of rice bran oil
Burlando et al. Therapeutic properties of rice constituents and derivatives (Oryza sativa L.): A review update
US20100086638A1 (en) Feed formulations containing docosahexaenoic acid
Kolodziejczyk et al. The application of flax and hemp seeds in food, animal feed and cosmetics production
Surendiran et al. Nutritional constituents and health benefits of wild rice (Zizania spp.)
JP6414774B2 (en) In vivo lipid deposition inhibitor, feed and breeding method
SA00210496B1 (en) Products containing corn oil and corn flour produced from corn with a high percentage of oils
GB2437909A (en) Animal feed comprising docosahexaenois acid from a microbial source
JP4785140B2 (en) Food material having lipid metabolism regulating action, health food, animal feed and animal breeding method
Ergönül et al. Cold pressed camelina (Camelina sativa L.) seed oil
KR100999429B1 (en) Yeast hydrolysate which has obesity treatment and antioxidative function
JP2020147582A (en) Composition for arthritis, mobility and delay ageing
Callaway et al. Hempseed oil
KR20220011253A (en) Food 3d printing with vegetable meat
Dharavath et al. Camelina sativa (L.) Crantz A mercantile crop with speckled pharmacological activities
Sulistyowati et al. Quality of milk fatty acid during late lactation in dairy goat fed on PUFA-diet supplemented with yeast and
Trebušak et al. Effect of dietary linseed oil and Ganoderma lucidum or olive leaves supplementation on fatty acid composition and oxidative status of rabbits
Falowo Potential of medicinal plants as Hypocholesterolemic agents in chicken meat production
JP2009291187A (en) Food composition for improving eating habit
Rahman et al. Ameliorating Effect of Dietary Sesame Oil on High Erucic Acid Rapeseed Powder–Induced Changes of Blood Serum Lipids in Rats
Vidal et al. Fish-derived functional foods and cardiovascular health: An overview of current developments and advancements
Nurtiana et al. Bekatul Beras sebagai Pencegah Kanker Kolon
JP6470230B2 (en) Oryzanol egg
JPH02290812A (en) Antiallergic fat and oil composition
JP2010105923A (en) PPARdelta EXPRESSION PROMOTER CONTAINING MATERIAL ORIGINATED FROM BARK OF GENUS ACACIA

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080714

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110329

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110614

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110708

R150 Certificate of patent or registration of utility model

Ref document number: 4785140

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140722

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350